Highlights of This Issue 107

CELL CYCLE AND SENESCENCE

109 Knockdown of PAK4 or PAK1 Inhibits the Proliferation of Mutant KRAS Colon Cancer Cells Independently of RAF/MEK/ERK and PI3K/AKT Signaling
Hana Tabusa, Teresa Brooks, and Andrew J. Massey

DNA DAMAGE AND REPAIR

161 MYC-Induced Epigenetic Activation of GATA4 in Lung Adenocarcinoma
Inés C. Castro, Achim Breiling, Katharina Luethkenhaus, Fatih Ceteci, Simone Hausmann, Sebastian Kress, Frank Lyko, Thomas Rudel, and Ulf R. Rapp

CELL DEATH AND SURVIVAL

122 Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon, Luca Mologni, William Bisson, Leonardo Scapozza, and Carlo Gambacorti-Passerini

133 The ATPase Activity of Reptin Is Required for Its Effects on Tumor Cell Growth and Viability in Hepatocellular Carcinoma
Aude Grigoletto, Véronique Neaud, Nathalie Allain-Courtois, Patrick Lestienne, and Jean Rosenbaum

140 Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
Daisuke Minami, Nagio Takigawa, Hiromasa Takeda, Minoru Takata, Nobuaki Ochi, Eiki Ichihara, Akiko Hisamoto, Katsuyuki Hotta, Mitsune Tanimoto, and Katsuyuki Kiura

CHROMATIN, GENE, AND RNA REGULATION

149 CPEB1 Regulates the Expression of MTDH/AEG-1 and Glioblastoma Cell Migration
Dawn M. Kochanek and David G. Wells

ONCOGENES AND TUMOR SUPPRESSORS

173 CREB-Binding Protein Regulates Ku70 Acetylation in Response to Ionization Radiation in Neuroblastoma
Chitra Subramanian, Manila Hada, Anthony W. Opipari Jr, Valerie P. Castle, and Roland P.S. Kwok

182 miRNA-145 Targets v-ets Erythroblastosis Virus E26 Oncogene Homolog 1 to Suppress the Invasion, Metastasis, and Angiogenesis of Gastric Cancer Cells
Liduan Zheng, Jiarui Pu, Teng Qi, Meng Qi, Dan Li, Xuan Xiang, Kai Huang, and Qiangsong Tong

SIGNAL TRANSDUCTION

194 CLT1 Targets Bladder Cancer through Integrin α5β1 and CLIC3
Lynn M. Knowles, James Zewe, Gunjan Malik, Anil V. Parwani, Jeffrey R. Gingrich, and Jan Pilch
ABOUT THE COVER

Crizotinib is a selective ALK inhibitor, recently approved for the treatment of ALK+ non-small cell lung cancer and currently in clinical trials for other ALK-related malignancies. By using a human cell-based screening approach, the appearance of two point mutations able to confer crizotinib resistance was observed. One of these mutations is sensitive to two structurally unrelated ALK inhibitors, NVP-TAE 684 and the clinically relevant AP26113, while the second one is resistant to all drugs. For further details, please see Ceccon and colleagues on page 122 in this issue.